Hong-Hong Yan

Ying Cheng, Yi-long Wu, Zhidong Liu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Jian Su, Qing Zhou, Hai-Yan Tu, 2016, Clinical Cancer Research.

Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.

Yi-long Wu, W. Zhong, M. Cheng, 2020, Cancer treatment and research communications.

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2014, Lung cancer.

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

Yi-long Wu, W. Zhong, Chongrui Xu, 2014, Lung cancer.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Yi-long Wu, Y. Wu, C. Zhou, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

X. Yi, C. Deng, Yi-long Wu, 2020, Thoracic cancer.

Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R

Jin-Ji Yang, Yilong Wu, Y. Lei, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Visceral pleural invasion in T1 tumors (≤3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Journal of thoracic disease.

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2015, Journal of Hematology & Oncology.

High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin

Hong-Hong Yan, Yunzhong Zhang, Yuzhen Guo, 2019, Medicine.

Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients

Jin-Ji Yang, W. Feng, Xuchao Zhang, 2023, Therapeutic advances in medical oncology.

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer

X. Yi, Jin-Ji Yang, Xue-Ning Yang, 2022, Cancer discovery.

Clinical Utility of Cerebrospinal Fluid Cell‐Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK‐Rearranged NSCLC

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Clinical lung cancer.

Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2011, Nuclear medicine communications.

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2012, Medical Oncology.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2019, Lung cancer.

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Cell reports. Medicine.

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2021, Experimental Hematology & Oncology.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

Yi-long Wu, S. An, Zhi-hong Chen, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay

Yi-long Wu, W. Zhong, S. An, 2014, Chinese journal of cancer.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2023, EClinicalMedicine.

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Decreased Expression of SOX7 is Correlated with Poor Prognosis in Lung Adenocarcinoma Patients

B. Li, Yangde Zhang, Bo-yun Huang, 2012, Pathology & Oncology Research.

Lack of incremental value of three-dimensional measurement in assessing invasiveness for lung cancer

Chao Zhang, Xue-Ning Yang, W. Zhong, 2023, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2023, Cancer cell.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2017, The Lancet. Respiratory medicine.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yi-long Wu, Jin-Ji Yang, Hong-Hong Yan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Science bulletin.

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705).

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2022, Clinical lung cancer.

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Nature Communications.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2022, Lung cancer.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Clinical lung cancer.

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

X. Yi, Yi-long Wu, W. Zhong, 2020, EBioMedicine.

TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer.

Chao Zhang, Xue-Ning Yang, W. Zhong, 2019, Translational lung cancer research.

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2017, British Journal of Cancer.

Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.

Chao Zhang, Xue-Ning Yang, Yuhua Gong, 2024, JAMA oncology.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Lung cancer.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Jian Su, Jun Zhao, Qing Zhou, 2018, BMC Cancer.

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy

S. An, Zhi-hong Chen, Qing Zhou, 2014, Cancer Gene Therapy.

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

Ying Cheng, Yi-long Wu, Zhidong Liu, 2021, JTO clinical and research reports.

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.

Yi-long Wu, Jin-Ji Yang, Xuchao Zhang, 2020, Lung cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.